CLIFFORD C. STEPHAN

The paper identifies collateral sensitivity to MEK inhibition in MTAP-null NSCLC cells that develop resistance to PRMT5 inhibitors.

The paper identifies a druggable groove on DeltaFOSB that allows small molecules to modulate its DNA binding and release, with one compound reducing genomic occupancy by 60% in vivo.

This study identifies a link between the ETV5/p38 signaling axis and aggressive thyroid cancers, showing that combining p38 inhibitors with BRAF inhibitors improves treatment outcomes.

This study identifies paclitaxel as a synergistic partner for trametinib in KRAS-mutated colorectal cancer, showing enhanced anti-tumor effects in vitro and in vivo.

This study identifies DNA2 nuclease as a therapeutic target for cancer by showing its overexpression in pancreatic cancer and its role in HR repair, with inhibitors reducing tumor growth and HR repair.